17. Multiple system atrophy Clinical trials / Disease details
Clinical trials : 118 / Drugs : 163 - (DrugBank : 49) / Drug target genes : 61 - Drug target pathways : 112
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04680065 (ClinicalTrials.gov) | April 2022 | 15/12/2020 | GDNF Gene Therapy for Multiple System Atrophy | Randomized, Double-Blind, Placebo-controlled Safety Study of Glial Cell Line-Derived Neurotrophic Factor Gene Transfer (AAV2-GDNF) in Multiple System Atrophy | Multiple System Atrophy | Biological: AAV2-GDNF gene therapy;Procedure: Sham (Placebo) Surgery | Brain Neurotherapy Bio, Inc. | NULL | Not yet recruiting | 35 Years | 75 Years | All | 9 | Phase 1 | United States |